It was approved by the US FDA in 2013 for late stage NSCLC, in 2016 for squamous cell carcinoma of the lung, and in 2018 for EGFR mutation-positive NSCLC (Table 2). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.